Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC)

European Urology

Volumn 46, Issue 3, 2004, Pages 339-343

  Gontero, Paolo ^a   Casetta, Giovanni ^b   Maso, Gloria ^a   Sogni, Filippo ^a   Pretti, Giuliano ^a   Zitella, Andrea ^b   Frea, Bruno ^a   Tizzani, Alessandro ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Gemcitabine; Intravesical; Marker lesion; Superficial bladder cancer

Indexed keywords

ANTIINFECTIVE AGENT; EPIRUBICIN; GEMCITABINE;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DYSURIA; FATIGUE; FEMALE; HEMATURIA; HUMAN; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; SAMPLE SIZE; SIDE EFFECT; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR LOCALIZATION; URINARY TRACT INFECTION; URINARY URGENCY;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 4043085510     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.05.001     Document Type: Article

References (24)

1. Oosterlinck W., Lobel B., Jakse G., Malmstrom P.U., Stockle M., Sternberg C. Guidelines on bladder cancer. European Association of Urology (EAU) Working Group on Oncological Urology. Eur. Urol. 41(2):2002;105-112
2. Huland H., Otto U., Droese M., Kloppel G. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. J. Urol. 132:1994;27-29
3. Koga H., Kuroiwa K., Yamaguchi A., Osada Y., Tsuneyoshi M., Naito S. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J. Urol. 171(1):2004;153-157
4. Lamm D.L., Blumenstein B.A., Crissman J.D., Montie J.E., Gottesman J.E., Lowe B.A., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J. Urol. 163:2000;1124-1129
5. Sylvester R.J., van der Meijden A.P.M., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168(5):2002;1964-1970
6. Stadler W.M., Kuzel T., Roth B., Raghavan D., Dorr F.A. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol. 15:1997;3394-3398
7. Cozzi P.J., Bajorin D.F., Tong W., Nguyen H., Scott J., Heston W.D.W., et al. Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin. Cancer Res. 5:1999;2629-2637
8. Kilani R.T., Tamini Y., Karmali S., Mackey J., Hanel E.G., Wong K.K., et al. Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anticancer Drug. 13(6):2002;557-566
9. Shipley L.A., Brown T.J., Compropst J.D., Hamilton M., Daniles W.D., Culp H.W. Metabolism and disposition of gemcitabine, an oncolytic deoxycytidine analog, in mice, rats and dogs. Drug Metab. Dispos. 20:1992;849-855
10. Witjes J.A., van der Heijden A.G., Vriesema J.L., Peters G.J., Laan A., Schalken J.A. Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur. Urol. 45(2):2004;182-186
11. Laufer M., Ramalingam S., Schoenberg M.P., Haisfield-Wolf M.E., Zuhowski E.G., Trueheart I.N., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the blood: a phase I and pharmacokinetic study. J. Clin. Oncol. 21(4):2003;697-703
12. Dalbagni G., Russo P., Sheinfeld J., Mazumdar M., Tong W., Rabbani F., et al. Phase I trial of intravesical Gemcitabine in Bacillus Calmette-Guerin - refractory transitional-cell-carcinoma of the bladder. J. Clin. Oncol. 20(15):2002;3193-3198
13. Lamm D.L., van der Meijden A.P.M., Akaza H. Intravesical chemo- and immunotherapy. How do we assess their effectiveness and what are their limitations and uses? Proceedings of the Fourth International Bladder Cancer Consensus Conference. Int. J. Urol. 2(Suppl 2):1995;23-35
14. van der Meijden A.P.M., Hall R.R., Kurth K.H., Bouffioux C.H. Phase II trials in Ta, T1 bladder cancer. The marker tumour concept (Review). Br. J. Urol. 77:1996;634-637
15. Hall R.R. Transurethral resection for transitional cell carcinoma. Probl. Urol. 6:1992;460-470
16. Van der Meijden A.P.M., Hall R.R., Pavone Macaluso M., Pawinsky A., Sylvester R., Van Glabbeke M. Marker tumour response to the sequential combination of intravesical therapy with Mitomycin C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organization for Research and Treatment on Cancer- Genitourinary Group (EORTC 30897). Eur. Urol. 29:1996;199-203
17. Fellows G., Parmar M., Grigor R., Hall R.R., Heal M.R., Wallace M.A. Marker tumour response to Evans and Pasteur BCG in multiple recurrent pTa, pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br. J. Urol. 73:1994;639-644
18. Popert R.J.M., Goodall J., Coptcoat M.J., Thompson P.M., Parmar M.K.B. Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of Epirubicin. Br. J. Urol. 74:1994;195-196
19. Mack D., Holtl W., Bassi P., Brausi M., Ferrari P., de Balincourt C. Sylvester R and members of the European Organization for Research and Treatment of Cancer Genitourinary Group. The ablative effect of quarter dose BCG on a papillary lesion of the bladder. J. Urol. 165:2001;401-403
20. De Berardinis E, Codacci Pisanelli G, Antonini G, Di Silverio F. Somministrazione endovescicale di gemcitabina nelle neoplasie superficiali della vescica: valutazione degli effetti collaterali (Studio di fase I). In: XI Congresso Nazionale SIUrO. 2001 [Abstract C17].
21. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 13(3):2003;176-181
22. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials. 10(1):1989;1-10
23. McCullough L.B. Ethical issues in the use of tumor markers in clinical investigation of the management of bladder cancer. Urol. Oncol. 7:2002;35-37
24. Huncharek M., Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am. J. Clin. Oncol. 26(4):2003;402-407